[November 25, 2014] |
|
Stealth BioTherapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference on December 3, 2014
NEWTON, Mass. --(Business Wire)--
Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage
biopharmaceutical company committed to bringing therapies that target
mitochondrial dysfunction to patients with severe acute and chronic
diseases, today announced that Travis Wilson, Chief Executive Officer,
is presenting a corporate overview at Piper Jaffray's 26th
Annual Healthcare Conference.
The presentation will take place on Wednesday, December 3, 2014 at 10:50
a.m. EST at The New York Palace Htel in New York, NY.
About Stealth BioTherapeutics
Stealth BioTherapeutics is a privately-held biopharmaceutical company
committed to bringing mitochondria-targeted therapeutics to patients to
treat both common and rare diseases. As the key common
element in a variety of serious, debilitating diseases, mitochondria -
the cell's energy source - offer a promising yet untapped therapeutic
target for diseases with significant unmet treatment needs. Stealth is
developing its lead compounds Bendavia™ and Ocuvia™ in multiple
therapeutic areas, including cardio-renal diseases, ophthalmic disorders
and orphan mitochondrial diseases, and defining the broad potential of
mitochondria-targeted therapies. Stealth's promising pipeline of
preclinical and clinical compounds is supported by more than 100
independent, peer-reviewed publications, abstracts and presentations.
[ Back To TMCnet.com's Homepage ]
|